Clinical Trials Logo

Clinical Trial Summary

Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.


Clinical Trial Description

This is an open-label, phase II, multicentre, randomised (1:1) clinical trial of an interventional medicinal product. This study will open at 3 centres across the UK. King's College Hospital NHS Foundation Trust will act as the coordinating centre for the study.

In this study, treatment with Lutathera will be compared to treatment with current best supportive care (somatostatin analogues) in patients with inoperable, somatostatin receptor positive, histologically confirmed small bowel NENs and these patients should have stable disease according to RECIST criteria for a period of 6 months prior to study entry.

Patients on the treatment arm will receive four administrations of 7.4 GBq (200 mCi) of Lutathera (and concomitant amino acids will be given with each administration for kidney protection). Patients are scheduled to continue to receive study treatment until any of the following occurs:

1. Unacceptable toxicity;

2. Progressive disease as determined by RECIST Criteria;

3. Inability or unwillingness of the patient to comply with study procedures;

4. Patient withdraws consent to participate Patients on the best supportive care arm will receive somatostatin analogue treatment every 4 weeks according to local standard of care practices.

Tumour response in both arms will be assessed after cycles 2 and 4 of 177Lu-Dotatate therapy, or every 16 weeks for patients enrolled under the best supportive care arm, according to RECIST criteria.

The study population is comprised of patients with stable carcinoid heart disease (CHD) and carcinoid syndrome. King's College Hospital performed surgery on 30 patients with carcinoid heart disease over the last 5 years. On review of patient records at King's, a further 30 patients with carcinoid heart disease were identified during the same time period who did not require surgery.

Other centres participating in this study have similar populations of patients with CHD, with specific multi-disciplinary team meetings and outpatient clinics for identification and recruitment of suitable patients into the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04039516
Study type Interventional
Source King's College Hospital NHS Trust
Contact
Status Not yet recruiting
Phase Phase 2
Start date October 2020
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT04993261 - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Early Phase 1
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Active, not recruiting NCT03375320 - Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 3
Completed NCT01435122 - A Study of Axitinib in Advanced Carcinoid Tumors Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Completed NCT00780663 - Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Phase 2
Completed NCT03723499 - Endoscopic Treatment of Bronchial Carcinoid Tumors
Recruiting NCT04017104 - Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT00328497 - A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors Phase 2
Completed NCT02399215 - Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT03420521 - Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Phase 2
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Not yet recruiting NCT02038738 - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00446082 - Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Phase 1
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Completed NCT01466036 - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 2
Completed NCT01398306 - Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.